


**CENTER FOR DRUG EVALUATION AND
RESEARCH**

APPLICATION NUMBER:

203441Orig1s000

STATISTICAL REVIEW(S)



U.S. Department of Health and Human Services
Food and Drug Administration
Center for Drug Evaluation and Research
Office of Translational Sciences
Office of Biostatistics

STATISTICAL REVIEW AND EVALUATION

CLINICAL STUDIES

NDA/BLA #: NDA 203-441

Supplement #:

Drug Name: GATTEX[®] (teduglutide) 0.05 mg/kg/day powder for subcutaneous injection

Indication(s): The treatment of adult patients with Short Bowel Syndrome (SBS)

Applicant: NPS Pharmaceuticals, Inc.

Date(s): Stamp Date: November 30, 2011
PDUFA Goal date: December 30, 2012

Review Priority: Standard with Major Amendment (13 month review cycle)

Biometrics Division: Division of Biometrics III

Statistical Reviewer: Behrang Vali M.S.

Concurring Reviewers: Mike Welch Ph.D.

Medical Division: Division of Gastroenterology and Inborn Errors Products

Clinical Team: MO: John Troiani, M.D.
MOTL and CDTL: Ruyi He, M.D.

Project Manager: Matthew C. Scherer M.B.A.

Keywords: NDA review, Clinical Studies

TABLE OF CONTENTS

| | | |
|----------|--------------------------------------------------------------------|-----------|
| 1 | EXECUTIVE SUMMARY | 5 |
| 2 | INTRODUCTION | 6 |
| 2.1 | OVERVIEW..... | 6 |
| 2.2 | DATA SOURCES | 7 |
| 3 | STATISTICAL EVALUATION | 7 |
| 3.1 | DATA AND ANALYSIS QUALITY | 8 |
| 3.1.1 | CL-0600-004..... | 8 |
| 3.1.2 | CL-0600-020..... | 8 |
| 3.2 | EVALUATION OF EFFICACY | 8 |
| 3.2.1 | Study Design and Endpoints..... | 8 |
| 3.2.2 | Statistical Methodologies..... | 15 |
| 3.2.3 | Patient Disposition, Demographic and Baseline Characteristics..... | 18 |
| 3.2.4 | Results and Conclusions | 24 |
| 3.3 | EVALUATION OF SAFETY | 36 |
| 3.4 | BENEFIT-RISK ASSESSMENT | 36 |
| 4 | FINDINGS IN SPECIAL/SUBGROUP POPULATIONS | 36 |
| 4.1 | GENDER, RACE, AGE, AND GEOGRAPHIC REGION | 36 |
| 4.2 | OTHER SPECIAL/SUBGROUP POPULATIONS | 37 |
| 5 | SUMMARY AND CONCLUSIONS | 37 |
| 5.1 | STATISTICAL ISSUES | 37 |
| 5.2 | COLLECTIVE EVIDENCE..... | 37 |
| 5.3 | CONCLUSIONS AND RECOMMENDATIONS | 38 |

LIST OF TABLES

| | |
|-------------------------------------------------------------------------------------------------------------|----|
| Table 1 Summary Information for Relevant Clinical Trials | 7 |
| Table 2 Criterion Values for Graded Response | 12 |
| Table 3 Disposition CL-0600-004 | 19 |
| Table 4 Demographic and Baseline Characteristics CL-0600-004 | 20 |
| Table 5 Disposition CL-0600-020 | 22 |
| Table 6 Demographic and Baseline Characteristics CL-0600-020 | 23 |
| Table 7 Number and Percent of Patients by Graded Response CL-0600-004 | 24 |
| Table 8 Number and Percent of Patients with Binary Response CL-0600-004 | 25 |
| Table 9 Number and Percent of Patients with at least 1-day Reduction in weekly PN Usage CL-0600-004 | 26 |
| Table 10 Change from Baseline in Weekly PN kilojoules CL-0600-004 | 26 |
| Table 11 Change from Baseline in Weekly PN Volume CL-0600-004 | 27 |
| Table 12 Change from Baseline in Plasma Citrulline CL-0600-004 | 28 |
| Table 13 Number and Percent of Patients with Binary Response CL-0600-020 | 30 |
| Table 14 Percent Change from Baseline to Last Dosing Visit in Weekly PN Volume CL-0600-020 | 32 |
| Table 15 Duration of Response CL-0600-020 | 33 |
| Table 16 Patients with 20% or 2L Reduction in PN Volume at Week 20, Maintained to Week 24 CL-0600-020 | 33 |
| Table 17 Patients who stop PN Usage CL-0600-020 | 34 |
| Table 18 Number and Percent of Patients by Graded Response CL-0600-020 | 34 |

LIST OF FIGURES

| | |
|-----------------------------------------------------------------------------------------------|----|
| Figure 1 Study Diagram CL-0600-004 | 9 |
| Figure 2 Study Diagram CL-0600-020 | 13 |
| Figure 3 Disposition CL-0600-004 | 19 |
| Figure 4 Disposition CL-0600-020 | 21 |
| Figure 5 Mean (\pm SE) PN Weekly Volume by Treatment Group – CL-0600-004/CL-0600-005 | 29 |
| Figure 6 Mean (\pm SE) PN Weekly Volume by Treatment Group – CL-0600-020/CL-0600-021 | 35 |

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.